Clinical Care Options Breast Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Breast Cancer: A Look Ahead to Practice-Changing Data at the 2016 Clinical Oncology Meeting
Discussion - Here are the breast cancer abstracts that I am most interested in hearing about at this year’s ASCO annual meeting. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - May 31, 2016 Category: Cancer & Oncology Source Type: research

Metastatic Breast Cancer: Experts Discuss the Impact of Therapeutic Complexity on Practice Patterns in America
Learning Module - Francisco J. Esteva, MD, PhD; Sara Hurvitz, MD; Mohammad Jahanzeb, MD, FACP; Kathy Miller, MD; and Nicholas Robert, MD, discuss the latest data and guideline recommendation and provide important practical insights on the management of patients with metastatic breast cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - May 24, 2016 Category: Cancer & Oncology Source Type: research

Metastatic Breast Cancer: Experts Discuss the Impact of Therapeutic Complexity on Practice Patterns in America
Slideset - In this downloadable slideset, Francisco J. Esteva, MD, PhD; Sara Hurvitz, MD; Mohammad Jahanzeb, MD, FACP; Kathy Miller, MD; and Nicholas Robert, MD, review the latest data and guideline recommendations in the management of patients with metastatic breast cancer including promising treatment approaches for these patients. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - May 24, 2016 Category: Cancer & Oncology Source Type: research

Targeting Androgen Receptor Signaling as a Therapeutic Strategy for Women With Triple-Negative Breast Cancer
Clinical Focus - Denise A. Yardley, MD, explores key agents in one of the most promising investigational treatment approaches for patients with TNBC: inhibition of androgen pathway signaling. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - May 5, 2016 Category: Cancer & Oncology Source Type: research

Targeting Androgen Receptor Signaling as a Therapeutic Strategy for Women With Triple-Negative Breast Cancer
Slideset - In this downloadable slideset, Denise A. Yardley, MD, reviews the most recent advances in understanding AR+ TNBC and the promising treatment approaches for this patient population. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - May 5, 2016 Category: Cancer & Oncology Source Type: research

New Developments in Breast Cancer
Slideset - In this downloadable slideset, Mohammad Jahanzeb, MD, FACP, and Joyce O’Shaughnessy, MD, review key studies in early and advanced breast cancer presented at the 2015 San Antonio Breast Cancer Symposium (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - January 11, 2016 Category: Cancer & Oncology Source Type: research

Abemaciclib + Endocrine or HER2-Targeted Therapies in Metastatic Breast Cancer
Slideset - Abemaciclib combined with endocrine or HER2-targeted therapies was safe and active in patients with MBC. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 18, 2015 Category: Cancer & Oncology Source Type: research

BCIRG 006: 10-Yr Follow-up of Adjuvant AC → T Compared With AC → TH and TCH for HER2+ Early BC
Slideset - This long-term follow-up analysis demonstrated a sustained advantage of adjuvant therapy with trastuzumab-containing regimens over the non-trastuzumab control in patients with HER2+ early breast cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 18, 2015 Category: Cancer & Oncology Source Type: research

WSG-ADAPT TN: Neoadjuvant Albumin-Bound Paclitaxel + Carboplatin or Gemcitabine in TNBC
Slideset - In patients with triple-negative breast cancer, 12 weeks of albumin-bound paclitaxel plus carboplatin significantly increased pCR rate vs albumin-bound paclitaxel plus gemcitabine. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 17, 2015 Category: Cancer & Oncology Source Type: research

Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer
Slideset - This single-arm phase II study demonstrated enhanced cell cycle arrest with the addition of palbociclib to neoadjuvant anastrozole in patients with ER+/HER2- early breast cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 16, 2015 Category: Cancer & Oncology Source Type: research

BELLE-2: Fulvestrant ± Buparlisib in HR+/HER2- Advanced Breast Cancer
Slideset - The combination of the investigational PI3K inhibitor buparlisib with fulvestrant extended PFS in patients with HR+/HER2- advanced breast cancer who progressed on previous AI therapy. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 16, 2015 Category: Cancer & Oncology Source Type: research

GeparSixto: Neoadjuvant Chemotherapy ± Carboplatin in Patients With HER2-Positive or Triple-Negative Early Breast Cancer
Slideset - Adding carboplatin to neoadjuvant chemotherapy significantly improved DFS in triple-negative but not HER2+ early breast cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 16, 2015 Category: Cancer & Oncology Source Type: research

CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
Slideset - Phase III study of adjuvant capecitabine in patients with HER2-negative breast cancer and pathologic residual disease following standard anthracycline/taxane neoadjuvant chemotherapy. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 15, 2015 Category: Cancer & Oncology Source Type: research

KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer
Slideset - Preliminary data show efficacy and manageable toxicity in 25 patients with PD-L1+, ER+/HER2- advanced breast cancer. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 15, 2015 Category: Cancer & Oncology Source Type: research